Delivery of the Active Substance Mirvetuximabum Tender - 142274992

Procurement Summary

Country: Poland

Summary: Delivery of the Active Substance Mirvetuximabum Soravtansinum Used in the B.50 Drug Program for the Treatment of Ovarian Cancer Patients

Deadline: 12 Jun 2026

Posting Date: 29 May 2026

Other Information

Notice Type: Tender

TOT Ref.No.: 142274992

Document Ref. No.: 365133-2026

Competition: ICB

Financier: Self Financed

Purchaser Ownership: Public

Tender Value: PLN 6466000

CPV Classification

33652100 - Antineoplastic agents

Purchaser's Detail

Name: Login to see tender_details

Address: Login to see tender_details

Email: Login to see tender_details

Login to see details

Tender Details

Delivery of the active substance mirvetuximabum soravtansinum used in the B.50 drug program for the treatment of ovarian cancer patients 1. The subject of the order is the supply of the active substance mirvetuximabum soravtansinum used in the B.50 drug treatment program patients with ovarian cancer for the needs of the Department of Surgical Gynecology and Gynecological Oncology for Adults and Girls USK-2 PUM in Szczecin. The description of the subject of the order and the estimated quantities of the products were included in the unit price form (Annex 2 to SWZ, hereinafter also referred to as FCJ). 2. The Ordering Party requires the offer of medicinal products in accordance with the Act of September 6, 2001, Pharmaceutical Law (Journal of Laws 2001.126.1381, as amended), placed on the market and used in the territory of the Republic of Poland in accordance with applicable regulations. 3. The Ordering Party requires that the offered medicinal products be included in Annex B to the Announcement of the Minister of Health on the list of reimbursed medicines (medicines available in drug programs) and the price offered cannot exceed the financing limit for a given active substance. 4. Failure to meet the condition described in points 2 and 3 will result in rejection of the offer. 5. The Ordering Party requires that the shelf life of all offered products be at least 12 years months, counting from the date of delivery to the ordering party's registered office. 6. The quantities of the goods constituting the subject of the order specified in the annex to the contract are estimated values ​​used to correctly calculate the price...
Document Type: Contract Notice Reference Number: ZP.220.89.26 Contract Type: supplies Estimated Value: 6466000 - PLN Authority Type: body-pl Doc Title: Delivery of the active substance mirvetuximabum soravtansinum used in the B.50 drug program for the treatment of patients to ovarian cancer Dispatch Date: 2026-05-27 Publish Date: 2026-05-28 Submission Date: 2026-06-12

Documents

 Tender Notice